For example, there is solid evidence linking IL-2 receptor subunit alpha (IL-2ra) increasing variants to elevated risk for multiple sclerosis (MS) and Crohn’s disease (CD)17 Aldesleukin, a recombinant form of IL-2 approved for cancer indications, is currently under investigation in a phase-2 clinical trial for CD (ClinicalTrials.gov ID: NCT04263831)45. Here, IL2 is linked to myeloid sarcoma.